Latest

• Preventive care of the future? Economic analysis of cardiovascular risk management.

  Some innovative medical clinics provide an alternative to the traditional curative care provided in the public health system, especially in hospitals. »

• The costs of Immunoglobulin treatment in hospital and in the home in Quebec

  Study examines the improvements in cost and quality of service arising from administration of Ig treatments in the home as opposed to in a hospital setting. »

• Coverage of new medicines in Federal-Provincial public drug plans in Canada 2009-2018

  Data reflect poorly on prospects for national pharmacare and the performance of the pan-Canadian Pharmaceutical Alliance (pCPA). »

• Coverage of new medicines in private versus public drug plans in Canada 2009-2018

  Public plans cover far fewer new drugs compared to private plans in Canada. Public plans also take much longer to cover new drugs compared to private plans. »

• Clinical Duty to Recontact in Genetic Testing: Insights from the Safety-Related Duty to Recall.

  When the understanding of relevant science no longer supports prior interpretation of a test result, is there a duty to recontact previously tested patients to inform them of the implications of these changes? »

• Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB.

  PMPRB regulatory changes will likely cause a substantial decline in the number of industry-funded clinical trials in Canada. »

• Medical resources and spending across provincial healthcare systems in Canada.

  Analysis links the availability of new drugs to lower overall health spending. »

• HTA and public coverage of new mental health drugs in Quebec and Canada.

  INESSS v CDR and RAMQ v ROC »

• Medical Resources in Canada and OECD countries. 2019 Edition.

  Canada’s health system supplies patients with fewer medical resources than the health systems of most OECD countries. »